GLP-1 Prior Authorization Requirements 2026: Ozempic, Wegovy & Mounjaro
2026 PA criteria for Ozempic, Wegovy, Mounjaro & Zepbound by payer. BMI thresholds, step therapy requirements, failed-drug documentation, and free LMN templates.
The GLP-1 Approval Landscape
GLP-1 receptor agonists are the most tightly managed drug class in commercial benefits. Plan sponsors have watched monthly spend triple since 2023, and nearly every major payer has responded with stricter prior authorization criteria. First-pass approval rates for obesity-indicated GLP-1s now sit below 40% on many plans.
The good news: when the documentation is complete and payer-specific criteria are addressed, approval rates climb above 80%.
Diabetes Indication vs. Obesity Indication
Ozempic and Mounjaro are FDA-approved for type 2 diabetes. Wegovy and Zepbound are FDA-approved for chronic weight management. Payer criteria differ dramatically between the two indications, so the first step is making sure the request matches the approved use.
Typical Payer Criteria for Obesity GLP-1s
Most commercial plans require all of the following for Wegovy or Zepbound:
- ✓ BMI ≥ 30, OR BMI ≥ 27 with at least one weight-related comorbidity (HTN, T2DM, dyslipidemia, OSA)
- ✓ Documented participation in a comprehensive weight management program for ≥ 6 months
- ✓ Prior trial and failure of lifestyle intervention (diet + exercise)
- ✓ Some plans: trial of phentermine, orlistat, or Contrave first
- ✓ No contraindications (personal/family hx of MTC, MEN2, pancreatitis)
BMI Documentation Pitfalls
Document height, weight, BMI, and the date measured in the clinic. Self-reported BMI is usually rejected. If your EMR auto-calculates, include the measurement date — payers will deny "current BMI" claims older than 90 days.
Step Therapy Strategy
Most plans require 1-2 prior agents for obesity. Acceptable prior trials usually include phentermine, orlistat, Contrave, Qsymia, or Saxenda. Document dose, duration, and reason for discontinuation (weight loss plateau, side effects, contraindication).
Comorbidity Documentation
For BMI 27-29, the comorbidity must be well-documented. "History of hypertension" is weak. "Hypertension on lisinopril 20mg, most recent BP 142/88" is strong. Pull labs for dyslipidemia (LDL, TG), HbA1c for prediabetes, and AHI for OSA.
Common Denial Reasons and How to Beat Them
- ✓ "Lifestyle intervention not documented" → Add clinic notes showing counseling dates and specific recommendations
- ✓ "Not medically necessary" → Cite AACE/TOS/ASMBS obesity guidelines and patient-specific comorbidities
- ✓ "Non-formulary" → Submit formulary exception with clinical justification
- ✓ "Step therapy not completed" → Document each prior trial with dates/doses/outcomes
- ✓ "Quantity limit" → Most GLP-1s have 1 pen per week default; weight-based dosing exceptions require evidence
Appeal Success Rates
Internal appeals for GLP-1 denials succeed 35-50% of the time when the appeal is well-documented. Peer-to-peer success rates are higher — around 55-65% when the clinician comes prepared with guideline citations. External review overturns another 30% of the remaining denials.
Payer-by-Payer Criteria Cheat Sheet
Here's how the eight biggest commercial payers handle GLP-1 prior authorization as of 2026. Criteria change frequently — always verify the current policy.
- ✓ UnitedHealthcare: BMI ≥30 or ≥27 + comorbidity, 6mo lifestyle intervention, 2 prior weight-loss agents for Wegovy/Zepbound
- ✓ Aetna (CPB 0039): BMI ≥30 or ≥27 + comorbidity, documented 6mo commercial weight program, no MTC/MEN2 history
- ✓ Cigna (Coverage Policy IP0249): BMI ≥30 or ≥27 + comorbidity, 6mo lifestyle program, step therapy: phentermine or Contrave
- ✓ Anthem BCBS: requires endocrinologist evaluation for some plans, BMI criteria + lifestyle + step therapy
- ✓ Humana (Medical Coverage Policy): Medicare plans exclude obesity indications (AIM-HIGH ruling); diabetes only
- ✓ Kaiser Permanente: internal formulary — Wegovy non-covered on most plans, Zepbound requires 3mo lifestyle
- ✓ BCBS Federal: covers GLP-1 for T2DM with metformin trial; obesity excluded unless diabetes comorbidity
- ✓ Medicare Part D (all plans): T2DM indications covered with PA; obesity indications excluded per CMS
Drug-Specific LMN Resources
Every GLP-1 has unique criteria quirks. Detailed drug-specific guides with LMN templates and payer-by-payer breakdowns:
- ✓ Ozempic (semaglutide for T2DM): see /lmn/ozempic for prior authorization template
- ✓ Wegovy (semaglutide for obesity): see /lmn/wegovy for BMI documentation and appeal strategy
- ✓ Mounjaro (tirzepatide for T2DM): see /lmn/mounjaro for A1C and metformin documentation
- ✓ Zepbound (tirzepatide for obesity): see /lmn/zepbound for comorbidity and lifestyle documentation
- ✓ Rybelsus (oral semaglutide): see /lmn/rybelsus if listed — oral alternative for patients declining injections
- ✓ Trulicity (dulaglutide): see /lmn/trulicity for once-weekly dulaglutide PA template
Fast-Track Your Approval in 3 Moves
If you're short on time, these three moves resolve the majority of GLP-1 denials:
- ✓ 1. Quote the payer's own medical policy number verbatim in your letter (e.g., "Per Aetna CPB 0039, section II, criteria 1-4 are met as follows...")
- ✓ 2. Document every failed prior therapy with exact dates, doses, and reasons (never "failed phentermine" — always "phentermine 37.5mg daily 03/2024-09/2024, d/c due to insomnia and elevated HR")
- ✓ 3. Attach the most recent in-clinic BMI measurement (≤90 days old) and contemporaneous comorbidity labs
2026 Formulary & Coverage Changes
Several major payers updated their GLP-1 policies in late 2025 and early 2026. Staying current on these changes is essential — submitting under an outdated policy is one of the most avoidable denial causes.
- ✓ Medicare Part D (2026): CMS now permits coverage of Wegovy for members with established cardiovascular disease (BMI ≥27) following the SURMOUNT-MMO trial results. Select Part D sponsors have activated this benefit — verify the patient's specific PDP before assuming exclusion.
- ✓ UnitedHealthcare (2026): Requires re-prior-authorization after 12 months for GLP-1 obesity indication. Flag patients who started therapy in 2024–2025 for renewal submissions.
- ✓ Cigna/Express Scripts (Jan 2026): Added a prescriber attestation requirement — BMI must be measured in-clinic within 60 days of submission. Self-reported BMI is explicitly excluded.
- ✓ Aetna (Q1 2026): Now requires documentation of a structured weight-management program (organized multidisciplinary program) rather than general lifestyle counseling. Office-based nutrition counseling alone no longer satisfies this criterion.
- ✓ Humana (commercial plans): Dropped Zepbound from most commercial formularies mid-2025; Wegovy is now the preferred tirzepatide/semaglutide obesity agent on most Humana commercial plans.
- ✓ BCBS plans (varies): Several regional Blues tightened quantity limits on Wegovy and Ozempic to a 28-day supply per fill — confirm with the local plan before prescribing a 90-day supply.
How RxCheckUp Handles GLP-1 PAs
RxCheckUp's GLP-1 workflow auto-populates the BMI, comorbidity, and prior therapy fields from the chart, pulls the exact payer criteria for the patient's plan (all 62 supported payers), and drafts a letter that addresses each criterion explicitly. Clinicians sign and submit in under 5 minutes. First-pass approval rates with RxCheckUp-generated LMNs average 82% for GLP-1s.